pamol 1000 mg tabletti
orifarm healthcare a/s - paracetamol - tabletti - 1000 mg - parasetamoli
tagrisso
astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
hydrocortison 1 % emulsiovoide
orion corporation - hydrocortisone - emulsiovoide - 1 % - hydrokortisoni
hydrocortison 2.5 % emulsiovoide
orion corporation - hydrocortisone - emulsiovoide - 2.5 % - hydrokortisoni
pantyson 10 mg/g + 20 mg/g emulsiovoide
orion corporation - dexpanthenol, hydrocortisone - emulsiovoide - 10 mg/g + 20 mg/g - hydrokortisoni
sibicort 10 mg/g + 10 mg/g emulsiovoide
orion corporation - chlorhexidine digluconate, hydrocortisone - emulsiovoide - 10 mg/g + 10 mg/g - hydrokortisoni ja antiseptit
hydrocortison 10 mg/ml liuos iholle
orion corporation - hydrocortisone - liuos iholle - 10 mg/ml - hydrokortisoni
hydrocortison 0.5 % emulsiovoide
orion corporation - hydrocortisone - emulsiovoide - 0.5 % - hydrokortisoni
zoviduo 50 mg/g + 10 mg/g emulsiovoide
haleon denmark aps - aciclovir, hydrocortisone - emulsiovoide - 50 mg/g + 10 mg/g - asikloviiri
verzenios
eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.